B&L invests in presbyopia

Article

Bausch & Lomb has made an equity investment in AcuFocus.

Bausch & Lomb has made an equity investment in - and secures an exclusive option to purchase - AcuFocus, a privately held company in California, USA.

AcuFocus is developing a corneal inlay, the ACI 7000, for the treatment of presbyopia. The inlay is implanted in the cornea under a LASIK flap and incorporates technology that increases a patient's depth of field, thereby improving near vision. The procedure involves no tissue removal and does not permanently alter the cornea, so pre-implant vision can be restored should the inlay be removed. Terms of the agreement were not disclosed.

Recent Videos
Quan Dong Nguyen, MD, MSc, of the Byers Eye Institute at Stanford University School of Medicine, discusses his presentation on Stargardt disease at the American Academy of Ophthalmology meeting
Abdelrahman Elhusseiny, MD, MSc, discusses his AAO presentation on risk of posterior capsular rupture in fellow-eyes cataract surgery
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
© 2024 MJH Life Sciences

All rights reserved.